Search - tctmd.com

Displaying 1 - 20 of 100

Sort: Relevancy | Date

Presentation TCT 2016

Novel DCB Coatings and Alternative Drugs: Are We Reaching the End of the Road?

Presenter: Fernando Alfonso, Juan F. Granada

November 01, 2016

Presentation TCT 2016

Methods and Technologies to Improve DCB Outcomes: Does the Data Support Their Use?

Presenter: Fernando Alfonso, Juan F. Granada, Azeem Latib

November 01, 2016

Presentation TCT 2016

DCB for De Novo Lesions: Clinical Applications and Technical Pitfalls

Presenter: Fernando Alfonso, Juan F. Granada, Bernardo Cortese

November 01, 2016

Presentation TCT 2016

DEBATE: DCB for In-Stent Restenosis: Does the Current Data Support Broad Adoption? Yes! The Data is Solid and DCB Should be the Treatment of Choice!

Presenter: Fernando Alfonso, Juan F. Granada, Bruno Scheller

November 01, 2016

Presentation TCT 2016

Designing a Complication-Free DCB: Is It Possible or Necessary?

Presenter: Koen Deloose, William A. Gray, Juan F. Granada

November 01, 2016

Presentation TCT 2016

DCB in BTK Intervention: Necessary Technical and Clinical Improvements to Unlock" the BTK Application

Presenter: Koen Deloose, William A. Gray, Mahmood K. Razavi

November 01, 2016

Presentation TCT 2016

Editorial Perspective: Given DCB Results, Is There Any Role for Stenting or Atherectomy in SFA Intervention?

Presenter: Koen Deloose, William A. Gray, Lawrence A. Garcia

November 01, 2016

Presentation TCT 2016

Impact of SFA Lesion Complexity: DCB Outcomes in the "Real-world"

Presenter: Koen Deloose, William A. Gray

November 01, 2016

Presentation TCT 2016

"DCB Efficacy In the SFA: Class-Effect or Device Specific"

Presenter: Koen Deloose, William A. Gray, Salvatore Cassese

November 01, 2016

Presentation TCT 2016

Rapid Fire Update: Latest Outcomes From the SFA Randomized Trials III - Stellarex

Presenter: Koen Deloose, William A. Gray, Prakash Krishnan

November 01, 2016

Presentation TCT 2016

Rapid Fire Update: Latest Outcomes From the SFA Randomized Trials II - Lutonix

Presenter: Koen Deloose, William A. Gray, Kenneth Rosenfield

November 01, 2016

Presentation TCT 2016

Rapid Fire Update: Latest Outcomes From the SFA Randomized Trials I - IN.PACT SFA

Presenter: Koen Deloose, William A. Gray, John R. Laird Jr.

November 01, 2016

Presentation TCT 2016

Overview of the Clinical Trials for Drug-Coated Balloons

Presenter: Schuyler Jones, Misti Malone, George Papandreou

October 30, 2016

Presentation ISET 2016

Drug-Coated Balloons for Renal FMD

Presenter: Fabrizio Fanelli

February 09, 2016

Presentation ISET 2016

Drug-Coated Balloons in the SFA: A Class of Devices with Differentiated Outcomes?

Presenter: Thomas Zeller

February 07, 2016

Presentation ISET 2016

Drug-Coated Balloons in the Venous Circulation: Is There a Place?

Presenter: Constantino Pe?a

February 05, 2016

Presentation

Effect of Drug-Coated Balloons (DCBs) inNative CAD Left With a Dissection

Presenter: Bernardo Cortese

November 29, 2015

Presentation TCT 2015

The Technological Evolution of Local Drug Delivery: Implications for the Clinical Adoption of Coronary DCBs

Presenter: Juan F. Granada, Bruno Scheller

October 13, 2015

Presentation TCT 2015

Life After the RIBS Trials: A Critical Overview of the Data and Implications for Clinical Practice

Presenter: Juan F. Granada, Bruno Scheller, Fernando Alfonso

October 13, 2015

Presentation TCT 2015

DCB for ISR Treatment: Technical Considerations for Optimization of Clinical Outcomes

Presenter: Juan F. Granada, Bruno Scheller, Pieter R. Stella

October 13, 2015

Advertisement

Novel DCB Coatings and Alternative Drugs: Are We Reaching the End of the Road?

Methods and Technologies to Improve DCB Outcomes: Does the Data Support Their Use?

DCB for De Novo Lesions: Clinical Applications and Technical Pitfalls

DEBATE: DCB for In-Stent Restenosis: Does the Current Data Support Broad Adoption? Yes! The Data is Solid and DCB Should be the Treatment of Choice!

Designing a Complication-Free DCB: Is It Possible or Necessary?

DCB in BTK Intervention: Necessary Technical and Clinical Improvements to Unlock" the BTK Application

Editorial Perspective: Given DCB Results, Is There Any Role for Stenting or Atherectomy in SFA Intervention?

Impact of SFA Lesion Complexity: DCB Outcomes in the "Real-world"

"DCB Efficacy In the SFA: Class-Effect or Device Specific"

Rapid Fire Update: Latest Outcomes From the SFA Randomized Trials III - Stellarex

Rapid Fire Update: Latest Outcomes From the SFA Randomized Trials II - Lutonix

Rapid Fire Update: Latest Outcomes From the SFA Randomized Trials I - IN.PACT SFA

Overview of the Clinical Trials for Drug-Coated Balloons

Drug-Coated Balloons for Renal FMD

Drug-Coated Balloons in the SFA: A Class of Devices with Differentiated Outcomes?

Drug-Coated Balloons in the Venous Circulation: Is There a Place?

Effect of Drug-Coated Balloons (DCBs) inNative CAD Left With a Dissection

The Technological Evolution of Local Drug Delivery: Implications for the Clinical Adoption of Coronary DCBs

Life After the RIBS Trials: A Critical Overview of the Data and Implications for Clinical Practice

DCB for ISR Treatment: Technical Considerations for Optimization of Clinical Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content